drugset / Trial / NCT05264493

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

NCT05264493

Phase 1 Completed 13 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

To compare the plasma concentration (bioavailability) and safety of a single naloxone 5 mg autoinjector intramuscular (IM) injection to a single 2 mg IM injection (an approved safe dose) and to a single 2 mg bolus intravenous (IV) injection (an approved safe dose)

Timeline

Start
2020-10-06
Primary completion
2021-01-08
Completion
2021-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 2 mg Intramuscular
Subject Naloxone Small molecule 5 mg Intramuscular

Indications

No indication recorded.